Cited by 235Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsFunctional Brain Connectivity Studies

Structural MRI biomarkers for preclinical and mild Alzheimer's disease

Open access
Fennema‐Notestine, Christine, Hagler, Donald J., McEvoy, Linda K., Fleisher, Adam S., Wu, Elaine H., Karow, David S., Dale, Anders M.·2009·Human Brain Mapping

Abstract

Noninvasive MRI biomarkers for Alzheimer's disease (AD) may enable earlier clinical diagnosis and the monitoring of therapeutic effectiveness. To assess potential neuroimaging biomarkers, the Alzheimer's Disease Neuroimaging Initiative is following normal controls (NC) and individuals with mild cognitive impairment (MCI) or AD. We applied high‐throughput image analyses procedures to these data to demonstrate the feasibility of detecting subtle structural changes in prodromal AD. Raw DICOM scans (139 NC, 175 MCI, and 84 AD) were downloaded for analysis. Volumetric segmentation and cortical surface reconstruction produced continuous cortical surface maps and region‐of‐interest (ROI) measures. The MCI cohort was subdivided into single‐ (SMCI) and multiple‐domain MCI (MMCI) based on neuropsychological performance. Repeated measures analyses of covariance were used to examine group and hemispheric effects while controlling for age, sex, and, for volumetric measures, intracranial vault. ROI analyses showed group differences for ventricular, temporal, posterior and rostral anterior cingulate, posterior parietal, and frontal regions. SMCI and NC differed within temporal, rostral posterior cingulate, inferior parietal, precuneus, and caudal midfrontal regions. With MMCI and AD, greater differences were evident in these regions and additional frontal and retrosplenial cortices; evidence for non‐AD pathology in MMCI also was suggested. Mesial temporal right‐dominant asymmetries were evident and did not interact with diagnosis. Our findings demonstrate that high‐throughput methods provide numerous measures to detect subtle effects of prodromal AD, suggesting early and later stages of the preclinical state in this cross‐sectional sample. These methods will enable a more complete longitudinal characterization and allow us to identify changes that are predictive of conversion to AD. Hum Brain Mapp 2009. © 2009 Wiley‐Liss, Inc.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hbm.20744

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Brain atrophy as revealed by structural MRI is able to discriminate preclinical stages and time evolution of Alzheimer's disease at 1-year follow-up.

    “it has been shown that brain atrophy as revealed by structural MRI is able to discriminate preclinical stages and time evolution of AD at 1‐year follow‐up. 34 , 35 , 36”

    From Early dementia diagnosis, MCI-to-dementia risk prediction, and the role of machine learning methods for feature extraction from integrated biomarkers, in particular for EEG signal analysis (2022) · cites this paper as [34]

    The Results and Discussion report MRI-detected atrophy differences among controls, MCI subgroups, and AD patients, supporting discrimination of early disease stages. But the study is cross-sectional: its Conclusions say longitudinal analyses were still underway. It does not demonstrate disease evolution at a 1-year follow-up. Page numbers are unavailable in our copy. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Killiany RJ Gomez-Isla T Moss M Kikinis R Sandor T Jolesz F Tanzi R Jones K Hyman BT Albert MS Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease Ann Neurol 2000 47 430 439 10762153

Cited by

Sorted by citations

Authors
Fennema‐Notestine, C., Hagler, D. J., McEvoy, L. K., Fleisher, A. S., Wu, E. H., Karow, D. S., & Dale, A. M.
Affiliations
University of California San Diego (US)
Corresponding author
Fennema‐Notestine, Christine
Venue
Human Brain Mapping
Publisher
Wiley
Published
2009-03-10
Volume
30
Issue
10
Pages
3238-3253
ISSN
  • 1065-9471 (ISSN-L)
  • 1097-0193
OpenAlex
W2079502798
Cited by
233
References
75
Citations by year
2026: 8 · 2025: 7 · 2024: 6 · 2023: 9 · 2022: 9 · 2021: 11 · 2020: 10 · 2019: 9 · 2018: 13 · 2017: 11 · 2016: 13 · 2015: 18 · 2014: 18 · 2013: 22 · 2012: 23
FWCI
14.18
Type
journal article
Language
en
Open access
Locations
  • Human Brain Mapping (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Foundation for the National Institutes of Health
  • National Institutes of Health (5u01ag024904-10)
  • National Institute on Aging (U01-AG-024904, U19AG010483)
  • National Center for Research Resources (U24RR021382)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Functional Brain Connectivity Studies
Keywords
Alzheimer's disease, mild cognitive impairment, preclinical Alzheimer's disease, structural MRI biomarkers, 3D image segmentation, cortical surface reconstruction, region of interest analysis, hemispheric lateralization, medial temporal lobe, conversion to Alzheimer's disease, high-throughput image analysis, Alzheimer's Disease Neuroimaging Initiative
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Cerebral Cortex, Cognition Disorders, Female, Humans, Image Processing, Computer-Assisted, Functional Laterality, Magnetic Resonance Imaging, Male, Mental Status Schedule, Middle Aged, Neuropsychological Tests, Cohort Studies, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review